​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics (AXSM) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $175.25, with a high of $216.00 and a low of $135.00. This represents a 67.75% increase from the last price of $104.47.

$50 $90 $130 $170 $210 $250 High: $216 Avg: $175.25 Low: $135 Last Closed Price: $104.47

AXSM Stock Rating

Axsome Therapeutics stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 25 0 Strong Sell Sell Hold Buy Strong Buy

AXSM Price Target Upside V Benchmarks

TypeNameUpside
StockAxsome Therapeutics67.75%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts1514
Avg Price Target$216.00$167.00$142.36
Last Closing Price$104.47$104.47$104.47
Upside/Downside106.76%59.85%36.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25512---17
Mar, 25512---17
Feb, 25511---16
Jan, 25512---17
Dec, 24512---17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 27, 2025Graig SuvannavejhMizuho Securities$216.00$121.7777.38%106.76%
Mar 03, 2025Robert W. Baird$160.00$127.1525.84%53.15%
Feb 03, 2025Graig SuvannavejhMizuho Securities$137.00$107.4327.52%31.14%
Feb 03, 2025Joon LeeTruist Financial$190.00$107.4376.86%81.87%
Feb 03, 2025Joel BeattyRobert W. Baird$132.00$107.4322.87%26.35%
Nov 12, 2024Yatin SunejaGuggenheim$135.00$99.4935.69%29.22%
Sep 11, 2024Graig SuvannavejhMizuho Securities$106.00$90.5817.02%1.46%
Sep 03, 2024Cerena ChenWells Fargo$140.00$88.8657.55%34.01%
Aug 06, 2024Raghuram SelvarajuH.C. Wainwright$180.00$83.21116.32%72.30%
Aug 06, 2024Jason GerberryBank of America Securities$106.00$83.9326.30%1.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 07, 2025JefferiesBuyBuyinitialise
Dec 31, 2024Cantor FitzgeraldOverweightOverweighthold
Dec 31, 2024H.C. WainwrightBuyBuyhold
Dec 31, 2024Wells FargoOutperformOutperformhold
Dec 31, 2024Morgan StanleyNegativeNegativehold
Dec 30, 2024RBC CapitalOutperformOutperformhold
Dec 30, 2024NeedhamBuyBuyhold
Nov 12, 2024GuggenheimBuyBuyhold
Oct 04, 2024Wells FargoBuyBuyhold
Sep 16, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-4 $2 $8 $14 $20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$-5.27$-5.99----
Avg Forecast$-4.33$-4.26$-5.46$-1.86$3.49$8.94$14.40
High Forecast$-3.58$-4.09$-4.84$1.33$7.55$15.48$18.28
Low Forecast$-5.22$-4.59$-6.42$-6.84$-1.77$1.68$11.37
Surprise %12.24%23.71%9.71%----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.04M$270.60M$385.69M----
Avg Forecast$46.98M$268.30M$384.09M$632.39M$1.02B$1.47B$2.00B
High Forecast$54.34M$269.66M$387.81M$761.98M$1.03B$1.47B$2.41B
Low Forecast$40.70M$265.55M$380.46M$529.02M$1.02B$1.47B$1.67B
Surprise %6.51%0.86%0.42%----

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-197.77M$-239.24M$-287.22M----
Avg Forecast$-196.81M$-197.28M$-255.63M$-117.53M$130.33M$454.59M$654.27M
High Forecast$-162.61M$-186.00M$-219.63M$60.27M$342.78M$703.18M$830.30M
Low Forecast$-236.92M$-208.57M$-291.63M$-310.79M$-80.59M$76.31M$516.45M
Surprise %0.49%21.27%12.36%----

AXSM Forecast FAQ

Is Axsome Therapeutics stock a buy?

Axsome Therapeutics stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Axsome Therapeutics is a favorable investment for most analysts.

What is Axsome Therapeutics's price target?

Axsome Therapeutics's price target, set by 25 Wall Street analysts, averages $175.25 over the next 12 months. The price target range spans from $135 at the low end to $216 at the high end, suggesting a potential 67.75% change from the previous closing price of $104.47.

How does Axsome Therapeutics stock forecast compare to its benchmarks?

Axsome Therapeutics's stock forecast shows a 67.75% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Axsome Therapeutics over the past three months?

  • April 2025: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 31.25% Strong Buy, 68.75% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Axsome Therapeutics’s EPS forecast?

Axsome Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.86, marking a -68.95% decrease from the reported $-5.99 in 2024. Estimates for the following years are $3.49 in 2026, $8.94 in 2027, and $14.4 in 2028.

What is Axsome Therapeutics’s revenue forecast?

Axsome Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $632.39M, reflecting a 63.96% increase from the reported $385.69M in 2024. The forecast for 2026 is $1.02B, followed by $1.47B for 2027, and $2B for 2028.

What is Axsome Therapeutics’s net income forecast?

Axsome Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-118M, representing a -59.08% decrease from the reported $-287M in 2024. Projections indicate $130.33M in 2026, $454.59M in 2027, and $654.27M in 2028.